#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Typical Ligands for Bile Acids
1-1	0-2	2.	_	_	_	_
1-2	3-10	Typical	abstract[1]	new[1]	coref	2-10[0_1]
1-3	11-18	Ligands	abstract[1]	new[1]	_	_
1-4	19-22	for	abstract[1]	new[1]	_	_
1-5	23-27	Bile	abstract[1]|plant|plant[3]	new[1]|new|new[3]	ana	2-7[0_3]
1-6	28-33	Acids	abstract[1]|plant[3]	new[1]|new[3]	_	_

#Text=BA targeted therapy is based on their receptors and ligands .
2-1	34-36	BA	abstract[4]	new[4]	_	_
2-2	37-45	targeted	abstract[4]	new[4]	_	_
2-3	46-53	therapy	abstract[4]	new[4]	_	_
2-4	54-56	is	_	_	_	_
2-5	57-62	based	_	_	_	_
2-6	63-65	on	_	_	_	_
2-7	66-71	their	plant|abstract[6]	giv|new[6]	coref	3-14[13_6]
2-8	72-81	receptors	abstract[6]	new[6]	_	_
2-9	82-85	and	_	_	_	_
2-10	86-93	ligands	abstract	giv	_	_
2-11	94-95	.	_	_	_	_

#Text=The regulation of BAs on other pathways occurs mainly through the activation of nuclear hormone receptors ( NHRs ) such as the farnesoid X receptor ( FXR ) , pregnane X receptor ( PXR ) , and vitamin D receptor ( VDR ) .
3-1	96-99	The	abstract[8]	new[8]	_	_
3-2	100-110	regulation	abstract[8]	new[8]	_	_
3-3	111-113	of	abstract[8]	new[8]	_	_
3-4	114-117	BAs	abstract[8]|abstract	new[8]|new	coref	12-8
3-5	118-120	on	abstract[8]	new[8]	_	_
3-6	121-126	other	abstract[8]|abstract[10]	new[8]|new[10]	_	_
3-7	127-135	pathways	abstract[8]|abstract[10]	new[8]|new[10]	_	_
3-8	136-142	occurs	_	_	_	_
3-9	143-149	mainly	_	_	_	_
3-10	150-157	through	_	_	_	_
3-11	158-161	the	event[11]	new[11]	ana	4-8[0_11]
3-12	162-172	activation	event[11]	new[11]	_	_
3-13	173-175	of	event[11]	new[11]	_	_
3-14	176-183	nuclear	event[11]|abstract[13]	new[11]|giv[13]	appos	3-18[0_13]
3-15	184-191	hormone	event[11]|substance|abstract[13]	new[11]|new|giv[13]	coref	5-12
3-16	192-201	receptors	event[11]|abstract[13]	new[11]|giv[13]	_	_
3-17	202-203	(	_	_	_	_
3-18	204-208	NHRs	abstract	giv	coref	4-5[27_0]
3-19	209-210	)	_	_	_	_
3-20	211-215	such	_	_	_	_
3-21	216-218	as	_	_	_	_
3-22	219-222	the	abstract[17]	new[17]	appos	3-27[0_17]
3-23	223-232	farnesoid	object|abstract[17]	new|new[17]	_	_
3-24	233-234	X	person|abstract[17]	new|new[17]	coref	3-31
3-25	235-243	receptor	abstract[17]	new[17]	_	_
3-26	244-245	(	_	_	_	_
3-27	246-249	FXR	abstract	giv	coref	6-14
3-28	250-251	)	_	_	_	_
3-29	252-253	,	_	_	_	_
3-30	254-262	pregnane	object|abstract[21]	new|new[21]	appos	3-34[0_21]
3-31	263-264	X	person|abstract[21]	giv|new[21]	coref	4-17
3-32	265-273	receptor	abstract[21]	new[21]	_	_
3-33	274-275	(	_	_	_	_
3-34	276-279	PXR	abstract	giv	coref	6-16
3-35	280-281	)	_	_	_	_
3-36	282-283	,	_	_	_	_
3-37	284-287	and	_	_	_	_
3-38	288-295	vitamin	substance[23]|abstract[24]	new[23]|new[24]	appos	3-42[0_24]
3-39	296-297	D	substance[23]|abstract[24]	new[23]|new[24]	_	_
3-40	298-306	receptor	abstract[24]	new[24]	_	_
3-41	307-308	(	_	_	_	_
3-42	309-312	VDR	abstract	giv	coref	4-15[32_0]
3-43	313-314	)	_	_	_	_
3-44	315-316	.	_	_	_	_

#Text=For the activation of these receptors , it is necessary that they interact with the retinoid X receptor as a heterodimer ( RXR ) .
4-1	317-320	For	_	_	_	_
4-2	321-324	the	event[26]	new[26]	coref	13-10[83_26]
4-3	325-335	activation	event[26]	new[26]	_	_
4-4	336-338	of	event[26]	new[26]	_	_
4-5	339-344	these	event[26]|abstract[27]	new[26]|giv[27]	ana	4-12[0_27]
4-6	345-354	receptors	event[26]|abstract[27]	new[26]|giv[27]	_	_
4-7	355-356	,	_	_	_	_
4-8	357-359	it	event	giv	_	_
4-9	360-362	is	_	_	_	_
4-10	363-372	necessary	_	_	_	_
4-11	373-377	that	_	_	_	_
4-12	378-382	they	abstract	giv	ana	5-3
4-13	383-391	interact	_	_	_	_
4-14	392-396	with	_	_	_	_
4-15	397-400	the	abstract[32]	giv[32]	coref	14-27[94_32]
4-16	401-409	retinoid	object|abstract[32]	new|giv[32]	_	_
4-17	410-411	X	person|abstract[32]	giv|giv[32]	_	_
4-18	412-420	receptor	abstract[32]	giv[32]	_	_
4-19	421-423	as	_	_	_	_
4-20	424-425	a	abstract[33]	new[33]	appos	4-23[0_33]
4-21	426-437	heterodimer	abstract[33]	new[33]	_	_
4-22	438-439	(	_	_	_	_
4-23	440-443	RXR	abstract	giv	coref	21-11
4-24	444-445	)	_	_	_	_
4-25	446-447	.	_	_	_	_

#Text=Afterwards , they act on various regulatory regions by binding to hormone response elements causing several genes to be up or downregulated in their transcription .
5-1	448-458	Afterwards	_	_	_	_
5-2	459-460	,	_	_	_	_
5-3	461-465	they	abstract	giv	_	_
5-4	466-469	act	_	_	_	_
5-5	470-472	on	_	_	_	_
5-6	473-480	various	place[36]	new[36]	_	_
5-7	481-491	regulatory	place[36]	new[36]	_	_
5-8	492-499	regions	place[36]	new[36]	_	_
5-9	500-502	by	_	_	_	_
5-10	503-510	binding	_	_	_	_
5-11	511-513	to	_	_	_	_
5-12	514-521	hormone	substance|abstract[39]	giv|new[39]	_	_
5-13	522-530	response	abstract|abstract[39]	new|new[39]	_	_
5-14	531-539	elements	abstract[39]	new[39]	_	_
5-15	540-547	causing	_	_	_	_
5-16	548-555	several	abstract[40]	new[40]	ana	5-24[0_40]
5-17	556-561	genes	abstract[40]	new[40]	_	_
5-18	562-564	to	_	_	_	_
5-19	565-567	be	_	_	_	_
5-20	568-570	up	_	_	_	_
5-21	571-573	or	_	_	_	_
5-22	574-587	downregulated	_	_	_	_
5-23	588-590	in	_	_	_	_
5-24	591-596	their	abstract|abstract[42]	giv|new[42]	_	_
5-25	597-610	transcription	abstract[42]	new[42]	_	_
5-26	611-612	.	_	_	_	_

#Text=Most BAs and the secondary BA , and LCA , are binding to FXR and PXR respectively .
6-1	613-617	Most	abstract[43]	new[43]	_	_
6-2	618-621	BAs	abstract[43]	new[43]	_	_
6-3	622-625	and	_	_	_	_
6-4	626-629	the	abstract[44]	new[44]	coref	8-7[0_44]
6-5	630-639	secondary	abstract[44]	new[44]	_	_
6-6	640-642	BA	abstract[44]	new[44]	_	_
6-7	643-644	,	_	_	_	_
6-8	645-648	and	_	_	_	_
6-9	649-652	LCA	abstract	new	coref	10-14
6-10	653-654	,	_	_	_	_
6-11	655-658	are	_	_	_	_
6-12	659-666	binding	_	_	_	_
6-13	667-669	to	_	_	_	_
6-14	670-673	FXR	abstract	giv	coref	7-2
6-15	674-677	and	_	_	_	_
6-16	678-681	PXR	abstract	giv	_	_
6-17	682-694	respectively	_	_	_	_
6-18	695-696	.	_	_	_	_

#Text=2.1. FXR
7-1	697-701	2.1.	_	_	_	_
7-2	702-705	FXR	abstract	giv	coref	8-1

#Text=FXR plays an important role in BA , glucose , and lipid metabolism .
8-1	706-709	FXR	abstract	giv	coref	11-11
8-2	710-715	plays	_	_	_	_
8-3	716-718	an	abstract[50]	new[50]	coref	23-10[140_50]
8-4	719-728	important	abstract[50]	new[50]	_	_
8-5	729-733	role	abstract[50]	new[50]	_	_
8-6	734-736	in	abstract[50]	new[50]	_	_
8-7	737-739	BA	abstract[50]|abstract|abstract[54]	new[50]|giv|new[54]	ana|coref	9-1[0_54]|14-5
8-8	740-741	,	abstract[50]|abstract[54]	new[50]|new[54]	_	_
8-9	742-749	glucose	abstract[50]|substance|abstract[54]	new[50]|new|new[54]	coref	17-19
8-10	750-751	,	abstract[50]|abstract[54]	new[50]|new[54]	_	_
8-11	752-755	and	abstract[50]|abstract[54]	new[50]|new[54]	_	_
8-12	756-761	lipid	abstract[50]|object|abstract[54]	new[50]|new|new[54]	coref	18-13
8-13	762-772	metabolism	abstract[50]|abstract[54]	new[50]|new[54]	_	_
8-14	773-774	.	_	_	_	_

#Text=It is most highly expressed in the liver , ileum , kidneys , and adrenal glands .
9-1	775-777	It	abstract	giv	coref	17-18[105_0]
9-2	778-780	is	_	_	_	_
9-3	781-785	most	_	_	_	_
9-4	786-792	highly	_	_	_	_
9-5	793-802	expressed	_	_	_	_
9-6	803-805	in	_	_	_	_
9-7	806-809	the	object[56]	new[56]	coref	13-2[79_56]
9-8	810-815	liver	object[56]	new[56]	_	_
9-9	816-817	,	_	_	_	_
9-10	818-823	ileum	object	new	coref	14-7[85_0]
9-11	824-825	,	_	_	_	_
9-12	826-833	kidneys	object	new	_	_
9-13	834-835	,	_	_	_	_
9-14	836-839	and	_	_	_	_
9-15	840-847	adrenal	object[59]	new[59]	_	_
9-16	848-854	glands	object[59]	new[59]	_	_
9-17	855-856	.	_	_	_	_

#Text=The strongest activator is CDCA , followed by DCA , CA , and LCA .
10-1	857-860	The	abstract[60]	new[60]	coref	10-5[61_60]
10-2	861-870	strongest	abstract[60]	new[60]	_	_
10-3	871-880	activator	abstract[60]	new[60]	_	_
10-4	881-883	is	_	_	_	_
10-5	884-888	CDCA	abstract[61]	giv[61]	coref	30-6[178_61]
10-6	889-890	,	abstract[61]	giv[61]	_	_
10-7	891-899	followed	abstract[61]	giv[61]	_	_
10-8	900-902	by	abstract[61]	giv[61]	_	_
10-9	903-906	DCA	abstract[61]|abstract	giv[61]|new	_	_
10-10	907-908	,	abstract[61]	giv[61]	_	_
10-11	909-911	CA	abstract[61]|abstract	giv[61]|new	_	_
10-12	912-913	,	abstract[61]	giv[61]	_	_
10-13	914-917	and	abstract[61]	giv[61]	_	_
10-14	918-921	LCA	abstract[61]|abstract	giv[61]|giv	coref	11-5
10-15	922-923	.	_	_	_	_

#Text=Despite the fact that LCA is a weak activator of FXR , it is a very strong downregulator of its function and thus could be termed a partial agonist .
11-1	924-931	Despite	_	_	_	_
11-2	932-935	the	abstract[65]	new[65]	_	_
11-3	936-940	fact	abstract[65]	new[65]	_	_
11-4	941-945	that	abstract[65]	new[65]	_	_
11-5	946-949	LCA	abstract[65]|abstract|abstract[67]	new[65]|giv|new[67]	coref	30-1
11-6	950-952	is	abstract[65]|abstract[67]	new[65]|new[67]	_	_
11-7	953-954	a	abstract[65]|abstract[67]	new[65]|new[67]	_	_
11-8	955-959	weak	abstract[65]|abstract[67]	new[65]|new[67]	_	_
11-9	960-969	activator	abstract[65]|abstract[67]	new[65]|new[67]	_	_
11-10	970-972	of	abstract[65]|abstract[67]	new[65]|new[67]	_	_
11-11	973-976	FXR	abstract[65]|abstract[67]|abstract	new[65]|new[67]|giv	ana	11-13
11-12	977-978	,	_	_	_	_
11-13	979-981	it	abstract	giv	coref	11-15[70_0]
11-14	982-984	is	_	_	_	_
11-15	985-986	a	abstract[70]	giv[70]	ana	11-20[0_70]
11-16	987-991	very	abstract[70]	giv[70]	_	_
11-17	992-998	strong	abstract[70]	giv[70]	_	_
11-18	999-1012	downregulator	abstract[70]	giv[70]	_	_
11-19	1013-1015	of	abstract[70]	giv[70]	_	_
11-20	1016-1019	its	abstract[70]|abstract|abstract[72]	giv[70]|giv|new[72]	coref|coref	12-11[77_72]|12-15
11-21	1020-1028	function	abstract[70]|abstract[72]	giv[70]|new[72]	_	_
11-22	1029-1032	and	_	_	_	_
11-23	1033-1037	thus	_	_	_	_
11-24	1038-1043	could	_	_	_	_
11-25	1044-1046	be	_	_	_	_
11-26	1047-1053	termed	_	_	_	_
11-27	1054-1055	a	abstract[73]	new[73]	_	_
11-28	1056-1063	partial	abstract[73]	new[73]	_	_
11-29	1064-1071	agonist	abstract[73]	new[73]	_	_
11-30	1072-1073	.	_	_	_	_

#Text=Controlling the synthesis and enterohepatic circulation of BAs , represents the major function of FXR .
12-1	1074-1085	Controlling	_	_	_	_
12-2	1086-1089	the	abstract[74]	new[74]	coref	17-24[107_74]
12-3	1090-1099	synthesis	abstract[74]	new[74]	_	_
12-4	1100-1103	and	_	_	_	_
12-5	1104-1117	enterohepatic	abstract[75]	new[75]	_	_
12-6	1118-1129	circulation	abstract[75]	new[75]	_	_
12-7	1130-1132	of	abstract[75]	new[75]	_	_
12-8	1133-1136	BAs	abstract[75]|abstract	new[75]|giv	coref	24-6
12-9	1137-1138	,	_	_	_	_
12-10	1139-1149	represents	_	_	_	_
12-11	1150-1153	the	abstract[77]	giv[77]	_	_
12-12	1154-1159	major	abstract[77]	giv[77]	_	_
12-13	1160-1168	function	abstract[77]	giv[77]	_	_
12-14	1169-1171	of	abstract[77]	giv[77]	_	_
12-15	1172-1175	FXR	abstract[77]|abstract	giv[77]|giv	coref	13-10
12-16	1176-1177	.	_	_	_	_

#Text=In the liver , bile flow is prompted through FXR activation .
13-1	1178-1180	In	_	_	_	_
13-2	1181-1184	the	object[79]	giv[79]	coref	19-7[0_79]
13-3	1185-1190	liver	object[79]	giv[79]	_	_
13-4	1191-1192	,	_	_	_	_
13-5	1193-1197	bile	substance|abstract[81]	new|new[81]	_	_
13-6	1198-1202	flow	abstract[81]	new[81]	_	_
13-7	1203-1205	is	_	_	_	_
13-8	1206-1214	prompted	_	_	_	_
13-9	1215-1222	through	_	_	_	_
13-10	1223-1226	FXR	abstract|event[83]	giv|giv[83]	coref	22-7[138_0]
13-11	1227-1237	activation	event[83]	giv[83]	_	_
13-12	1238-1239	.	_	_	_	_

#Text=After being activated through BA in the ileum , the expression of fibroblast growth factor 15/19 ( FGF15/19 ) increases , leading to an activation of fibroblast growth factor receptor 4 ( FGFR4 ) in hepatocytes (
14-1	1240-1245	After	_	_	_	_
14-2	1246-1251	being	_	_	_	_
14-3	1252-1261	activated	_	_	_	_
14-4	1262-1269	through	_	_	_	_
14-5	1270-1272	BA	abstract	giv	coref	33-7
14-6	1273-1275	in	_	_	_	_
14-7	1276-1279	the	object[85]	giv[85]	coref	31-15[0_85]
14-8	1280-1285	ileum	object[85]	giv[85]	_	_
14-9	1286-1287	,	_	_	_	_
14-10	1288-1291	the	abstract[86]	new[86]	_	_
14-11	1292-1302	expression	abstract[86]	new[86]	_	_
14-12	1303-1305	of	abstract[86]	new[86]	_	_
14-13	1306-1316	fibroblast	abstract[86]|event|abstract[89]	new[86]|new|new[89]	coref|coref	14-27|14-27[93_89]
14-14	1317-1323	growth	abstract[86]|abstract|abstract[89]	new[86]|new|new[89]	coref	14-28
14-15	1324-1330	factor	abstract[86]|abstract[89]	new[86]|new[89]	_	_
14-16	1331-1336	15/19	abstract[86]|abstract[89]	new[86]|new[89]	_	_
14-17	1337-1338	(	_	_	_	_
14-18	1339-1347	FGF15/19	_	_	_	_
14-19	1348-1349	)	_	_	_	_
14-20	1350-1359	increases	_	_	_	_
14-21	1360-1361	,	_	_	_	_
14-22	1362-1369	leading	_	_	_	_
14-23	1370-1372	to	_	_	_	_
14-24	1373-1375	an	event[90]	new[90]	_	_
14-25	1376-1386	activation	event[90]	new[90]	_	_
14-26	1387-1389	of	event[90]	new[90]	_	_
14-27	1390-1400	fibroblast	event[90]|event|abstract[93]|abstract[94]	new[90]|giv|giv[93]|giv[94]	appos|coref	14-33[0_94]|33-19[0_93]
14-28	1401-1407	growth	event[90]|abstract|abstract[93]|abstract[94]	new[90]|giv|giv[93]|giv[94]	_	_
14-29	1408-1414	factor	event[90]|abstract[93]|abstract[94]	new[90]|giv[93]|giv[94]	_	_
14-30	1415-1423	receptor	event[90]|abstract[94]	new[90]|giv[94]	_	_
14-31	1424-1425	4	event[90]|abstract[94]	new[90]|giv[94]	_	_
14-32	1426-1427	(	event[90]	new[90]	_	_
14-33	1428-1433	FGFR4	event[90]|abstract	new[90]|giv	coref	21-4
14-34	1434-1435	)	event[90]	new[90]	_	_
14-35	1436-1438	in	event[90]	new[90]	_	_
14-36	1439-1450	hepatocytes	event[90]|animal	new[90]|new	coref	31-23[187_0]
14-37	1451-1452	(	_	_	_	_

#Text=Figure 1
15-1	1453-1459	Figure	abstract[97]	new[97]	ana	17-1[0_97]
15-2	1460-1461	1	abstract[97]	new[97]	_	_

#Text=) .
16-1	1462-1463	)	_	_	_	_
16-2	1464-1465	.	_	_	_	_

#Text=This is of great importance as FGF15/19 is an ileum-derived enterokine that governs BA homeostasis , regulates hepatic glucose metabolism , and stimulates protein synthesis .
17-1	1466-1470	This	abstract	giv	_	_
17-2	1471-1473	is	_	_	_	_
17-3	1474-1476	of	_	_	_	_
17-4	1477-1482	great	abstract[99]	new[99]	_	_
17-5	1483-1493	importance	abstract[99]	new[99]	_	_
17-6	1494-1496	as	_	_	_	_
17-7	1497-1505	FGF15/19	substance	new	coref	17-9[101_0]
17-8	1506-1508	is	_	_	_	_
17-9	1509-1511	an	substance[101]	giv[101]	_	_
17-10	1512-1525	ileum-derived	substance[101]	giv[101]	_	_
17-11	1526-1536	enterokine	substance[101]	giv[101]	_	_
17-12	1537-1541	that	substance[101]	giv[101]	_	_
17-13	1542-1549	governs	substance[101]	giv[101]	_	_
17-14	1550-1552	BA	substance[101]|person|abstract[103]	giv[101]|new|new[103]	coref|coref	25-3[152_103]|32-5
17-15	1553-1564	homeostasis	substance[101]|abstract[103]	giv[101]|new[103]	_	_
17-16	1565-1566	,	substance[101]	giv[101]	_	_
17-17	1567-1576	regulates	substance[101]	giv[101]	_	_
17-18	1577-1584	hepatic	substance[101]|abstract[105]	giv[101]|giv[105]	coref	26-15[163_105]
17-19	1585-1592	glucose	substance[101]|substance|abstract[105]	giv[101]|giv|giv[105]	coref	32-7
17-20	1593-1603	metabolism	substance[101]|abstract[105]	giv[101]|giv[105]	_	_
17-21	1604-1605	,	substance[101]	giv[101]	_	_
17-22	1606-1609	and	substance[101]	giv[101]	_	_
17-23	1610-1620	stimulates	substance[101]	giv[101]	_	_
17-24	1621-1628	protein	substance[101]|substance|abstract[107]	giv[101]|new|giv[107]	coref	24-9[148_107]
17-25	1629-1638	synthesis	substance[101]|abstract[107]	giv[101]|giv[107]	_	_
17-26	1639-1640	.	_	_	_	_

#Text=If administered pharmacologically or expressed transgenically in mice , FGF19 increases hepatic lipid oxidation , reduces lipogenesis and protects from hepatosteatosis .
18-1	1641-1643	If	_	_	_	_
18-2	1644-1656	administered	_	_	_	_
18-3	1657-1674	pharmacologically	_	_	_	_
18-4	1675-1677	or	_	_	_	_
18-5	1678-1687	expressed	_	_	_	_
18-6	1688-1702	transgenically	_	_	_	_
18-7	1703-1705	in	_	_	_	_
18-8	1706-1710	mice	animal	new	coref	20-26[127_0]
18-9	1711-1712	,	_	_	_	_
18-10	1713-1718	FGF19	abstract	new	_	_
18-11	1719-1728	increases	_	_	_	_
18-12	1729-1736	hepatic	abstract[111]	new[111]	_	_
18-13	1737-1742	lipid	object|abstract[111]	giv|new[111]	coref	25-5
18-14	1743-1752	oxidation	abstract[111]	new[111]	_	_
18-15	1753-1754	,	_	_	_	_
18-16	1755-1762	reduces	_	_	_	_
18-17	1763-1774	lipogenesis	substance	new	_	_
18-18	1775-1778	and	_	_	_	_
18-19	1779-1787	protects	_	_	_	_
18-20	1788-1792	from	_	_	_	_
18-21	1793-1808	hepatosteatosis	animal	new	_	_
18-22	1809-1810	.	_	_	_	_

#Text=A lack of it causes impaired liver regeneration .
19-1	1811-1812	A	abstract[114]	new[114]	ana	19-4[0_114]
19-2	1813-1817	lack	abstract[114]	new[114]	_	_
19-3	1818-1820	of	abstract[114]	new[114]	_	_
19-4	1821-1823	it	abstract[114]|abstract	new[114]|giv	_	_
19-5	1824-1830	causes	_	_	_	_
19-6	1831-1839	impaired	event[117]	new[117]	_	_
19-7	1840-1845	liver	object|event[117]	giv|new[117]	coref	20-23[126_0]
19-8	1846-1858	regeneration	event[117]	new[117]	_	_
19-9	1859-1860	.	_	_	_	_

#Text=A lack of FGF 15 results in increased hepatic steatosis and in the development of endoplasmic reticulum ( ER ) stress in the liver of mice fed a high fat diet .
20-1	1861-1862	A	abstract[118]	new[118]	_	_
20-2	1863-1867	lack	abstract[118]	new[118]	_	_
20-3	1868-1870	of	abstract[118]	new[118]	_	_
20-4	1871-1874	FGF	abstract[118]|abstract[119]	new[118]|new[119]	_	_
20-5	1875-1877	15	abstract[118]|abstract[119]	new[118]|new[119]	_	_
20-6	1878-1885	results	_	_	_	_
20-7	1886-1888	in	_	_	_	_
20-8	1889-1898	increased	abstract[120]	new[120]	coref	34-24[229_120]
20-9	1899-1906	hepatic	abstract[120]	new[120]	_	_
20-10	1907-1916	steatosis	abstract[120]	new[120]	_	_
20-11	1917-1920	and	_	_	_	_
20-12	1921-1923	in	_	_	_	_
20-13	1924-1927	the	event[121]	new[121]	_	_
20-14	1928-1939	development	event[121]	new[121]	_	_
20-15	1940-1942	of	event[121]	new[121]	_	_
20-16	1943-1954	endoplasmic	event[121]|abstract|substance[123]|abstract[125]	new[121]|new|new[123]|new[125]	_	_
20-17	1955-1964	reticulum	event[121]|substance[123]|abstract[125]	new[121]|new[123]|new[125]	_	_
20-18	1965-1966	(	event[121]|abstract[125]	new[121]|new[125]	_	_
20-19	1967-1969	ER	event[121]|person|abstract[125]	new[121]|new|new[125]	_	_
20-20	1970-1971	)	event[121]|abstract[125]	new[121]|new[125]	_	_
20-21	1972-1978	stress	event[121]|abstract[125]	new[121]|new[125]	_	_
20-22	1979-1981	in	event[121]	new[121]	_	_
20-23	1982-1985	the	event[121]|object[126]	new[121]|giv[126]	coref	21-17[135_126]
20-24	1986-1991	liver	event[121]|object[126]	new[121]|giv[126]	_	_
20-25	1992-1994	of	event[121]|object[126]	new[121]|giv[126]	_	_
20-26	1995-1999	mice	event[121]|object[126]|animal[127]	new[121]|giv[126]|giv[127]	coref	34-5[224_127]
20-27	2000-2003	fed	event[121]|object[126]|animal[127]	new[121]|giv[126]|giv[127]	_	_
20-28	2004-2005	a	event[121]|object[126]|animal[127]|event[128]	new[121]|giv[126]|giv[127]|new[128]	_	_
20-29	2006-2010	high	event[121]|object[126]|animal[127]|event[128]	new[121]|giv[126]|giv[127]|new[128]	_	_
20-30	2011-2014	fat	event[121]|object[126]|animal[127]|event[128]	new[121]|giv[126]|giv[127]|new[128]	_	_
20-31	2015-2019	diet	event[121]|object[126]|animal[127]|event[128]	new[121]|giv[126]|giv[127]|new[128]	_	_
20-32	2020-2021	.	_	_	_	_

#Text=The activation of FGFR4 together with the activation of small heterodimer partner ( SHP ) in the liver , inhibits CYP7A1 .
21-1	2022-2025	The	event[129]	new[129]	_	_
21-2	2026-2036	activation	event[129]	new[129]	_	_
21-3	2037-2039	of	event[129]	new[129]	_	_
21-4	2040-2045	FGFR4	event[129]|abstract	new[129]|giv	coref	26-7[159_0]
21-5	2046-2054	together	event[129]|event[131]	new[129]|new[131]	_	_
21-6	2055-2059	with	event[129]|event[131]	new[129]|new[131]	_	_
21-7	2060-2063	the	event[129]|event[131]	new[129]|new[131]	_	_
21-8	2064-2074	activation	event[129]|event[131]	new[129]|new[131]	_	_
21-9	2075-2077	of	event[129]|event[131]	new[129]|new[131]	_	_
21-10	2078-2083	small	event[129]|event[131]|person[133]	new[129]|new[131]|new[133]	_	_
21-11	2084-2095	heterodimer	event[129]|event[131]|abstract|person[133]	new[129]|new[131]|giv|new[133]	_	_
21-12	2096-2103	partner	event[129]|event[131]|person[133]	new[129]|new[131]|new[133]	_	_
21-13	2104-2105	(	_	_	_	_
21-14	2106-2109	SHP	abstract	new	coref	25-8[153_0]
21-15	2110-2111	)	_	_	_	_
21-16	2112-2114	in	_	_	_	_
21-17	2115-2118	the	object[135]	giv[135]	coref	31-19[186_135]
21-18	2119-2124	liver	object[135]	giv[135]	_	_
21-19	2125-2126	,	_	_	_	_
21-20	2127-2135	inhibits	_	_	_	_
21-21	2136-2142	CYP7A1	abstract	new	coref	22-5
21-22	2143-2144	.	_	_	_	_

#Text=In order to downregulate CYP7A1 , intestinal-specific FXR is required .
22-1	2145-2147	In	_	_	_	_
22-2	2148-2153	order	_	_	_	_
22-3	2154-2156	to	_	_	_	_
22-4	2157-2169	downregulate	_	_	_	_
22-5	2170-2176	CYP7A1	abstract	giv	_	_
22-6	2177-2178	,	_	_	_	_
22-7	2179-2198	intestinal-specific	abstract[138]	giv[138]	coref	23-6[139_138]
22-8	2199-2202	FXR	abstract[138]	giv[138]	_	_
22-9	2203-2205	is	_	_	_	_
22-10	2206-2214	required	_	_	_	_
22-11	2215-2216	.	_	_	_	_

#Text=On the other hand , the liver-specific FXR plays an important role in the repression of the expression of CYP8B1 .
23-1	2217-2219	On	_	_	_	_
23-2	2220-2223	the	_	_	_	_
23-3	2224-2229	other	_	_	_	_
23-4	2230-2234	hand	_	_	_	_
23-5	2235-2236	,	_	_	_	_
23-6	2237-2240	the	abstract[139]	giv[139]	coref	24-14[0_139]
23-7	2241-2255	liver-specific	abstract[139]	giv[139]	_	_
23-8	2256-2259	FXR	abstract[139]	giv[139]	_	_
23-9	2260-2265	plays	_	_	_	_
23-10	2266-2268	an	abstract[140]	giv[140]	coref	32-18[198_140]
23-11	2269-2278	important	abstract[140]	giv[140]	_	_
23-12	2279-2283	role	abstract[140]	giv[140]	_	_
23-13	2284-2286	in	abstract[140]	giv[140]	_	_
23-14	2287-2290	the	abstract[140]|event[141]	giv[140]|new[141]	_	_
23-15	2291-2301	repression	abstract[140]|event[141]	giv[140]|new[141]	_	_
23-16	2302-2304	of	abstract[140]|event[141]	giv[140]|new[141]	_	_
23-17	2305-2308	the	abstract[140]|event[141]|abstract[142]	giv[140]|new[141]|new[142]	_	_
23-18	2309-2319	expression	abstract[140]|event[141]|abstract[142]	giv[140]|new[141]|new[142]	_	_
23-19	2320-2322	of	abstract[140]|event[141]|abstract[142]	giv[140]|new[141]|new[142]	_	_
23-20	2323-2329	CYP8B1	abstract[140]|event[141]|abstract[142]|abstract	giv[140]|new[141]|new[142]|new	_	_
23-21	2330-2331	.	_	_	_	_

#Text=One of the mechanisms for BAs to suppress their own synthesis is through FXR .
24-1	2332-2335	One	object[144]	new[144]	_	_
24-2	2336-2338	of	object[144]	new[144]	_	_
24-3	2339-2342	the	object[144]|abstract[145]	new[144]|new[145]	ana	24-9[0_145]
24-4	2343-2353	mechanisms	object[144]|abstract[145]	new[144]|new[145]	_	_
24-5	2354-2357	for	object[144]|abstract[145]	new[144]|new[145]	_	_
24-6	2358-2361	BAs	object[144]|abstract[145]|abstract	new[144]|new[145]|giv	coref	29-9
24-7	2362-2364	to	object[144]|abstract[145]	new[144]|new[145]	_	_
24-8	2365-2373	suppress	object[144]|abstract[145]	new[144]|new[145]	_	_
24-9	2374-2379	their	object[144]|abstract[145]|abstract|abstract[148]	new[144]|new[145]|giv|giv[148]	_	_
24-10	2380-2383	own	object[144]|abstract[145]|abstract[148]	new[144]|new[145]|giv[148]	_	_
24-11	2384-2393	synthesis	object[144]|abstract[145]|abstract[148]	new[144]|new[145]|giv[148]	_	_
24-12	2394-2396	is	_	_	_	_
24-13	2397-2404	through	_	_	_	_
24-14	2405-2408	FXR	abstract	giv	coref	25-1
24-15	2409-2410	.	_	_	_	_

#Text=FXR influences the hepatic lipid homeostasis via SHP , which reduces the expression of SREBP1 .
25-1	2411-2414	FXR	abstract	giv	_	_
25-2	2415-2425	influences	_	_	_	_
25-3	2426-2429	the	abstract[152]	giv[152]	_	_
25-4	2430-2437	hepatic	abstract[152]	giv[152]	_	_
25-5	2438-2443	lipid	object|abstract[152]	giv|giv[152]	coref	32-10
25-6	2444-2455	homeostasis	abstract[152]	giv[152]	_	_
25-7	2456-2459	via	_	_	_	_
25-8	2460-2463	SHP	abstract[153]	giv[153]	_	_
25-9	2464-2465	,	abstract[153]	giv[153]	_	_
25-10	2466-2471	which	abstract[153]	giv[153]	_	_
25-11	2472-2479	reduces	abstract[153]	giv[153]	_	_
25-12	2480-2483	the	abstract[153]|abstract[154]	giv[153]|new[154]	ana	26-1[0_154]
25-13	2484-2494	expression	abstract[153]|abstract[154]	giv[153]|new[154]	_	_
25-14	2495-2497	of	abstract[153]|abstract[154]	giv[153]|new[154]	_	_
25-15	2498-2504	SREBP1	abstract[153]|abstract[154]	giv[153]|new[154]	_	_
25-16	2505-2506	.	_	_	_	_

#Text=It also regulates the expression of peroxisome proliferator-activated receptor PPAR-α , a regulator of triglyceride metabolism , that can induce free fatty acid β-oxidation .
26-1	2507-2509	It	abstract	giv	coref	26-4[156_0]
26-2	2510-2514	also	_	_	_	_
26-3	2515-2524	regulates	_	_	_	_
26-4	2525-2528	the	abstract[156]	giv[156]	coref	32-25[201_156]
26-5	2529-2539	expression	abstract[156]	giv[156]	_	_
26-6	2540-2542	of	abstract[156]	giv[156]	_	_
26-7	2543-2553	peroxisome	abstract[156]|abstract|abstract[159]|abstract[160]	giv[156]|new|giv[159]|new[160]	_	_
26-8	2554-2576	proliferator-activated	abstract[156]|abstract|abstract[159]|abstract[160]	giv[156]|new|giv[159]|new[160]	_	_
26-9	2577-2585	receptor	abstract[156]|abstract[159]|abstract[160]	giv[156]|giv[159]|new[160]	_	_
26-10	2586-2592	PPAR-α	abstract[156]|abstract[160]	giv[156]|new[160]	_	_
26-11	2593-2594	,	_	_	_	_
26-12	2595-2596	a	substance[161]	new[161]	_	_
26-13	2597-2606	regulator	substance[161]	new[161]	_	_
26-14	2607-2609	of	substance[161]	new[161]	_	_
26-15	2610-2622	triglyceride	substance[161]|object|abstract[163]	new[161]|new|giv[163]	coref	32-5[196_163]
26-16	2623-2633	metabolism	substance[161]|abstract[163]	new[161]|giv[163]	_	_
26-17	2634-2635	,	_	_	_	_
26-18	2636-2640	that	_	_	_	_
26-19	2641-2644	can	_	_	_	_
26-20	2645-2651	induce	_	_	_	_
26-21	2652-2656	free	abstract[166]	new[166]	_	_
26-22	2657-2662	fatty	abstract|substance[165]|abstract[166]	new|new[165]|new[166]	_	_
26-23	2663-2667	acid	substance[165]|abstract[166]	new[165]|new[166]	_	_
26-24	2668-2679	β-oxidation	abstract[166]	new[166]	_	_
26-25	2680-2681	.	_	_	_	_

#Text=2.2.
27-1	2682-2686	2.2.	abstract	new	_	_

#Text=Takeda G-Protein-Coupled Receptor 5 ( TGR5 )
28-1	2687-2693	Takeda	person|substance[170]	new|new[170]	_	_
28-2	2694-2711	G-Protein-Coupled	abstract|substance[170]	new|new[170]	_	_
28-3	2712-2720	Receptor	substance[170]	new[170]	_	_
28-4	2721-2722	5	substance[170]	new[170]	_	_
28-5	2723-2724	(	_	_	_	_
28-6	2725-2729	TGR5	abstract	new	coref	29-1
28-7	2730-2731	)	_	_	_	_

#Text=TGR5 is a G-protein coupled membrane receptor that BAs activate .
29-1	2732-2736	TGR5	abstract	giv	coref	29-3[175_0]
29-2	2737-2739	is	_	_	_	_
29-3	2740-2741	a	abstract[175]	giv[175]	coref	30-10[0_175]
29-4	2742-2751	G-protein	substance|abstract[175]	new|giv[175]	_	_
29-5	2752-2759	coupled	abstract[175]	giv[175]	_	_
29-6	2760-2768	membrane	object|abstract[175]	new|giv[175]	_	_
29-7	2769-2777	receptor	abstract[175]	giv[175]	_	_
29-8	2778-2782	that	abstract[175]	giv[175]	_	_
29-9	2783-2786	BAs	abstract[175]|abstract	giv[175]|giv	_	_
29-10	2787-2795	activate	abstract[175]	giv[175]	_	_
29-11	2796-2797	.	_	_	_	_

#Text=LCA is considered to be the strongest activator of TGR5 among the main primary and secondary BAs .
30-1	2798-2801	LCA	abstract	giv	_	_
30-2	2802-2804	is	_	_	_	_
30-3	2805-2815	considered	_	_	_	_
30-4	2816-2818	to	_	_	_	_
30-5	2819-2821	be	_	_	_	_
30-6	2822-2825	the	abstract[178]	giv[178]	_	_
30-7	2826-2835	strongest	abstract[178]	giv[178]	_	_
30-8	2836-2845	activator	abstract[178]	giv[178]	_	_
30-9	2846-2848	of	abstract[178]	giv[178]	_	_
30-10	2849-2853	TGR5	abstract[178]|abstract	giv[178]|giv	ana	31-1
30-11	2854-2859	among	_	_	_	_
30-12	2860-2863	the	abstract[180]	new[180]	_	_
30-13	2864-2868	main	abstract[180]	new[180]	_	_
30-14	2869-2876	primary	abstract[180]	new[180]	_	_
30-15	2877-2880	and	abstract[180]	new[180]	_	_
30-16	2881-2890	secondary	abstract[180]	new[180]	_	_
30-17	2891-2894	BAs	abstract[180]	new[180]	_	_
30-18	2895-2896	.	_	_	_	_

#Text=It is widely expressed in the body , for example in the gallbladder , ileum , colon , liver ( not in hepatocytes though ) , brown adipose tissue ( BAT ) , nervous system , and muscle .
31-1	2897-2899	It	abstract	giv	coref	33-1
31-2	2900-2902	is	_	_	_	_
31-3	2903-2909	widely	_	_	_	_
31-4	2910-2919	expressed	_	_	_	_
31-5	2920-2922	in	_	_	_	_
31-6	2923-2926	the	object[182]	new[182]	_	_
31-7	2927-2931	body	object[182]	new[182]	_	_
31-8	2932-2933	,	_	_	_	_
31-9	2934-2937	for	_	_	_	_
31-10	2938-2945	example	object[183]	new[183]	_	_
31-11	2946-2948	in	object[183]	new[183]	_	_
31-12	2949-2952	the	object[183]	new[183]	_	_
31-13	2953-2964	gallbladder	object[183]	new[183]	_	_
31-14	2965-2966	,	_	_	_	_
31-15	2967-2972	ileum	object	giv	_	_
31-16	2973-2974	,	_	_	_	_
31-17	2975-2980	colon	place	new	_	_
31-18	2981-2982	,	_	_	_	_
31-19	2983-2988	liver	object[186]	giv[186]	_	_
31-20	2989-2990	(	object[186]	giv[186]	_	_
31-21	2991-2994	not	object[186]	giv[186]	_	_
31-22	2995-2997	in	object[186]	giv[186]	_	_
31-23	2998-3009	hepatocytes	object[186]|animal[187]	giv[186]|giv[187]	_	_
31-24	3010-3016	though	object[186]|animal[187]	giv[186]|giv[187]	_	_
31-25	3017-3018	)	object[186]	giv[186]	_	_
31-26	3019-3020	,	_	_	_	_
31-27	3021-3026	brown	substance[189]	new[189]	coref	32-35[207_189]
31-28	3027-3034	adipose	abstract|substance[189]	new|new[189]	coref	32-35[206_0]
31-29	3035-3041	tissue	substance[189]	new[189]	_	_
31-30	3042-3043	(	_	_	_	_
31-31	3044-3047	BAT	abstract	new	coref	32-25
31-32	3048-3049	)	_	_	_	_
31-33	3050-3051	,	_	_	_	_
31-34	3052-3059	nervous	abstract[191]	new[191]	_	_
31-35	3060-3066	system	abstract[191]	new[191]	_	_
31-36	3067-3068	,	_	_	_	_
31-37	3069-3072	and	_	_	_	_
31-38	3073-3079	muscle	object	new	_	_
31-39	3080-3081	.	_	_	_	_

#Text=Besides being involved in BA , glucose , and lipid metabolism , interestingly , it also plays a role in increasing the induction of BAT expression in thermogenesis and energy release via browning of white adipose tissue and .
32-1	3082-3089	Besides	_	_	_	_
32-2	3090-3095	being	_	_	_	_
32-3	3096-3104	involved	_	_	_	_
32-4	3105-3107	in	_	_	_	_
32-5	3108-3110	BA	person|abstract[196]	giv|giv[196]	ana	32-15[0_196]
32-6	3111-3112	,	abstract[196]	giv[196]	_	_
32-7	3113-3120	glucose	substance|abstract[196]	giv|giv[196]	coref	34-28
32-8	3121-3122	,	abstract[196]	giv[196]	_	_
32-9	3123-3126	and	abstract[196]	giv[196]	_	_
32-10	3127-3132	lipid	object|abstract[196]	giv|giv[196]	_	_
32-11	3133-3143	metabolism	abstract[196]	giv[196]	_	_
32-12	3144-3145	,	_	_	_	_
32-13	3146-3159	interestingly	_	_	_	_
32-14	3160-3161	,	_	_	_	_
32-15	3162-3164	it	abstract	giv	_	_
32-16	3165-3169	also	_	_	_	_
32-17	3170-3175	plays	_	_	_	_
32-18	3176-3177	a	abstract[198]	giv[198]	_	_
32-19	3178-3182	role	abstract[198]	giv[198]	_	_
32-20	3183-3185	in	abstract[198]	giv[198]	_	_
32-21	3186-3196	increasing	abstract[198]	giv[198]	_	_
32-22	3197-3200	the	abstract[198]|event[199]	giv[198]|new[199]	_	_
32-23	3201-3210	induction	abstract[198]|event[199]	giv[198]|new[199]	_	_
32-24	3211-3213	of	abstract[198]|event[199]	giv[198]|new[199]	_	_
32-25	3214-3217	BAT	abstract[198]|event[199]|abstract|abstract[201]	giv[198]|new[199]|giv|giv[201]	_	_
32-26	3218-3228	expression	abstract[198]|event[199]|abstract[201]	giv[198]|new[199]|giv[201]	_	_
32-27	3229-3231	in	abstract[198]|event[199]|abstract[201]	giv[198]|new[199]|giv[201]	_	_
32-28	3232-3245	thermogenesis	abstract[198]|event[199]|abstract[201]|abstract	giv[198]|new[199]|giv[201]|new	_	_
32-29	3246-3249	and	abstract[198]|event[199]|abstract[201]	giv[198]|new[199]|giv[201]	_	_
32-30	3250-3256	energy	abstract[198]|event[199]|abstract[201]|abstract|event[204]	giv[198]|new[199]|giv[201]|new|new[204]	coref	34-34
32-31	3257-3264	release	abstract[198]|event[199]|abstract[201]|event[204]	giv[198]|new[199]|giv[201]|new[204]	_	_
32-32	3265-3268	via	_	_	_	_
32-33	3269-3277	browning	event[205]	new[205]	_	_
32-34	3278-3280	of	event[205]	new[205]	_	_
32-35	3281-3286	white	event[205]|abstract[206]|substance[207]	new[205]|giv[206]|giv[207]	_	_
32-36	3287-3294	adipose	event[205]|abstract[206]|substance[207]	new[205]|giv[206]|giv[207]	_	_
32-37	3295-3301	tissue	event[205]|substance[207]	new[205]|giv[207]	_	_
32-38	3302-3305	and	_	_	_	_
32-39	3306-3307	.	_	_	_	_

#Text=TGR5 knockout leads to a changed BA composition and has anti-inflammatory properties by for example by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells ( NF-κB ) or LPS-induced production of inflammatory cytokines in macrophages .
33-1	3308-3312	TGR5	abstract|abstract[209]	giv|new[209]	coref|coref	34-5|34-5[223_209]
33-2	3313-3321	knockout	abstract[209]	new[209]	_	_
33-3	3322-3327	leads	_	_	_	_
33-4	3328-3330	to	_	_	_	_
33-5	3331-3332	a	abstract[211]	new[211]	_	_
33-6	3333-3340	changed	abstract[211]	new[211]	_	_
33-7	3341-3343	BA	abstract|abstract[211]	giv|new[211]	_	_
33-8	3344-3355	composition	abstract[211]	new[211]	_	_
33-9	3356-3359	and	_	_	_	_
33-10	3360-3363	has	_	_	_	_
33-11	3364-3381	anti-inflammatory	abstract[212]	new[212]	_	_
33-12	3382-3392	properties	abstract[212]	new[212]	_	_
33-13	3393-3395	by	_	_	_	_
33-14	3396-3399	for	_	_	_	_
33-15	3400-3407	example	_	_	_	_
33-16	3408-3410	by	_	_	_	_
33-17	3411-3421	inhibiting	_	_	_	_
33-18	3422-3429	nuclear	abstract[214]	new[214]	_	_
33-19	3430-3436	factor	abstract|abstract[214]	giv|new[214]	_	_
33-20	3437-3463	kappa-light-chain-enhancer	abstract[214]	new[214]	_	_
33-21	3464-3466	of	abstract[214]	new[214]	_	_
33-22	3467-3476	activated	abstract[214]|plant[216]	new[214]|new[216]	_	_
33-23	3477-3478	B	abstract[214]|person|plant[216]	new[214]|new|new[216]	_	_
33-24	3479-3484	cells	abstract[214]|plant[216]	new[214]|new[216]	_	_
33-25	3485-3486	(	_	_	_	_
33-26	3487-3492	NF-κB	substance	new	_	_
33-27	3493-3494	)	_	_	_	_
33-28	3495-3497	or	_	_	_	_
33-29	3498-3509	LPS-induced	event[218]	new[218]	_	_
33-30	3510-3520	production	event[218]	new[218]	_	_
33-31	3521-3523	of	event[218]	new[218]	_	_
33-32	3524-3536	inflammatory	event[218]|substance[219]	new[218]|new[219]	_	_
33-33	3537-3546	cytokines	event[218]|substance[219]	new[218]|new[219]	_	_
33-34	3547-3549	in	event[218]|substance[219]	new[218]|new[219]	_	_
33-35	3550-3561	macrophages	event[218]|substance[219]|animal	new[218]|new[219]|new	_	_
33-36	3562-3563	.	_	_	_	_

#Text=In another experiment , TGR5 knockout mice received a sleeve gastrectomy and it was shown how TGR5 is important in order to decrease hepatic steatosis , improve glucose control , and increase the energy expenditure post-surgery .
34-1	3564-3566	In	_	_	_	_
34-2	3567-3574	another	event[221]	new[221]	ana	34-13[0_221]
34-3	3575-3585	experiment	event[221]	new[221]	_	_
34-4	3586-3587	,	_	_	_	_
34-5	3588-3592	TGR5	abstract|abstract[223]|animal[224]	giv|giv[223]|giv[224]	coref	34-17
34-6	3593-3601	knockout	abstract[223]|animal[224]	giv[223]|giv[224]	_	_
34-7	3602-3606	mice	animal[224]	giv[224]	_	_
34-8	3607-3615	received	_	_	_	_
34-9	3616-3617	a	object[226]	new[226]	_	_
34-10	3618-3624	sleeve	object|object[226]	new|new[226]	_	_
34-11	3625-3636	gastrectomy	object[226]	new[226]	_	_
34-12	3637-3640	and	_	_	_	_
34-13	3641-3643	it	event	giv	_	_
34-14	3644-3647	was	_	_	_	_
34-15	3648-3653	shown	_	_	_	_
34-16	3654-3657	how	_	_	_	_
34-17	3658-3662	TGR5	abstract	giv	_	_
34-18	3663-3665	is	_	_	_	_
34-19	3666-3675	important	_	_	_	_
34-20	3676-3678	in	_	_	_	_
34-21	3679-3684	order	_	_	_	_
34-22	3685-3687	to	_	_	_	_
34-23	3688-3696	decrease	_	_	_	_
34-24	3697-3704	hepatic	abstract[229]	giv[229]	_	_
34-25	3705-3714	steatosis	abstract[229]	giv[229]	_	_
34-26	3715-3716	,	_	_	_	_
34-27	3717-3724	improve	_	_	_	_
34-28	3725-3732	glucose	substance|abstract[231]	giv|new[231]	_	_
34-29	3733-3740	control	abstract[231]	new[231]	_	_
34-30	3741-3742	,	_	_	_	_
34-31	3743-3746	and	_	_	_	_
34-32	3747-3755	increase	_	_	_	_
34-33	3756-3759	the	abstract[233]	new[233]	_	_
34-34	3760-3766	energy	abstract|abstract[233]	giv|new[233]	_	_
34-35	3767-3778	expenditure	abstract[233]	new[233]	_	_
34-36	3779-3791	post-surgery	_	_	_	_
34-37	3792-3793	.	_	_	_	_
